Member Info for Adastra

Incomprehensible that we are visiting lows as the pandemic recedes and confidence in recovery increases. Of all the shares in the FTSE 100 Smith and Nephew must have the most resilient platform for future growth even if the market crashes. Hips and knees are in massive demand as elective surgery reimerges and accelerates. No brainer up to £18.

With 5 day isolation on the cards and today's news that Spire is helping NHS the outlook is improving daily.
https://www.investegate.co.uk/spire-healthcare-grp--spi-/rns/agreement-in-principle-with-nhs-england/202201100700098485X/
How long can SN. toddle along at this derisory level before the market wakes up to the future prospects here?

Ditto. Been involved in pharmacy, healthcare and primary/secondary care since 1970'S and so know S&N well. The company is transforming and rationalizing it's business rapidly at present and embracing and addressing strong avenues into existing and new markets. I expect a lot and am sure that they have the right team and products now in place to meet or exceed those expectations. I am sure that I am not alone in this and that far bigger players are starting to eye the attractions as interest rate hikes limit upside elsewhere in 2022 and beyond.

Current consensus is understandably conservative given covid pressures. The potential triggers for upgrades in 2022 are myriad. Its easy to see the avenues for significant growth if things go to plan so the forward forecast p/e is pretty undemanding and should be subject to numerous revisions as covid diminishes and baclog is addressed.

Couldn't agree more with the logic but I expect a massively compressed timeframe. Once the covid reaction has eased and the smell of Spring starts to drift there should be a 'significant' rerate here. First movers like ourselves are either already loaded up or are climbing aboard. For me the trigger is Jan opening of LSE as I see a scramble to accumulate S&N as a pretty much solid play for 2022 with oodles of upside given the whopping backlog in the system of operations on hold. A very sweet resilient share and a peach at this price and up to £14.00 before the gap jump to £16/18 plus on news triggers.

Should give more clarity and focus plus hopefully a positive impact on sentiment.

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces that it will be holding a virtual Meet the Management event for institutional investors and analysts from 12:30pm GMT (7:30am EST) on 16 December 2021.



The event will consist of a formal presentation, followed by break-out group meetings with members of the senior leadership team including the Chief Executive Officer, Chief Financial Officer, and Presidents of the global franchises.



Institutional investors or analysts wishing to take part should register on the Smith+Nephew corporate website: www.smith-nephew.com/meetthemanagement .



Additionally, the formal presentation will be streamed live with a replay available after the event.

Assuming......and it's by no means certain yet....that Omicron is indeed less of a problem than the current restrictions indicate, the bounce back for S&N should be decent as we are heading to clear any perceived health service logjam into the New Year. The market should start to preempt that as first movers engage with the Share. All things being even, the 20 day ma should punch through the 50 day (currently 12.42 and 12.77 respectively). If this is a strong thrust upwards on volume, then the scene is set to attack the 200 day ma currently flattening at 14.07. A lot of negative sentiment is piled into the price at present so it would take a distinct shock imo to drop below 12.00 or $32 US adr. We will tread water around this level imo (12-13) before a sharp clic north on positive news......that could be provided by the Meet the Team event for analysts on Dec 16th next week.

Certainly not one that keeps me awake at night as any indication of overcoming the Omicron 'wave' will be seen as positive news for S&N.

S&N is like a coiled spring at present. Pressed down by current covid unknowns it could bounce very quickly indeed as sentiment changes. Pent up demand for hips, knees plus dressings and new compact AI surgery bode for an excellent future unconstrained as other sectors will be. It's purely a waiting game from now on. Predators MUST be eyeing S&N for reliable earnings post pandemic. As the at-risk winter scenario clears, investors (institutional and private) will load up for the rise ahead. The market is huge and growing since joint replacement ensures longer independence and reduces age-related health issues. A no-brainer once the covid mist even begins to clear. The new mega-factory in Malaysia opens in 2022 which should accelerate the growth markedly. Independently or assimilated, Smith and Nephew is a superstock on the runway. Prepare for take-off soon as it's pretty much certain to fill the Share of the Year 2022 list criteria for the paper jocks.

J&J would be better suitor given their objectives. Several private equity firms have been cited especially one wishing to divest Boots to concentrate on growth in US. S&N looks peach at this time.

Not at all greedy .... I've now got my average price down to just below £13 by reallocation of funds. Happy? YEP.

Last chance at £12.48 to buy............boing....

As either investor or predator. The darkest hour is the one before dawn ..... perfect.

With J&J splitting it's business and S&N now driving into cementless joints there couldn't be a more opportune time than this covid low for J&J to make it's eternally voiced move......small fry, Big potential given the huge manufacturing site that S&N are opening in Malaysia 2022....perfect for addressing the explosive far East markets.... just a thought as J&J have been a potential bidder for over 10 yrs. Not a better time as it splits to basics and S&N looks a snug fit.

This is being led by Covid fear and sentiment...
Look through the mist and either ride the impending upwave or lock into a gem of a share at a bargain basement price. The darkness of the covid tunnel will break and S&N will bounce back strongly into a secure healthstream.

Buyers finally mopping up last of hapless sellers as buying rates escalate and bookmakers release stock into the rise from here.....

Last bounce on the trampoline for this gem of a growth stock as all the sellers wash out and the buyers take control. Certainly didn't see this pullback but not unusual as covid dynamics influence it strongly. Having said that, Smith and Nephew will be flying when income stocks stall in 2022 and beyond. All short term pressures will ease and the outlook is exceptional, especially in the US where orthopaedic operations are transitioning to smaller sites where S&N already leads in sports orthopaedic....could be a huge factor in traction for next year. Also the Malaysian factory comes on line in the same year. Hold with patience or perhaps DTR and accumulate? Excellent resilience stock for a concerted rebound from here up. Unexpected but should recover strongly as covid pressures subdue since they are weighing heavily at present.

Apologies ... rose from $35.27 not $35.7

S&N rose from $35.7 on UK close yesterday to $35.87 at US close with volume up 400% on average......Got to follow suit and play catchup as demand is escalating.....

Whatever your opinion on the current Covid situation the underlying strengths and quality here will surface. Everyone wants to stay healthy and mobile as long as is possible....S&N provides the means to fulfil those wishes. Every hip and knee replaced keeps a potential long-term bed blocker out of the NHS longer. Investors are also concentrating on the UK.....the company is a huge worldwide player. Quality in a resilient sector will pay huge dividends.....patience and top ups should certainly win in the end.